Lei Fan

Union Hospital — China

Biochemistry, Genetics and Molecular Biology · Life Sciences

32h-index3.3kcitations104works9.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(17), Advanced Breast Cancer Therapies(11), Cancer-related molecular mechanisms research(10), HER2/EGFR in Cancer Research(10), Cancer Immunotherapy and Biomarkers(7)

Publications93 total

Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2− breast cancer: The LINUXtrial
Cancer Cell·2025
2722P Efficacy and safety of eribulin combined with anlotinib in patients with advanced liposarcoma and leiomyosarcoma
Annals of Oncology·2025
Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial
Nature Medicine·2025· 11 cited
Abstract GS3-06: Neoadjuvant camrelizumab plus chemotherapy (chemo) for early or locally advanced triple-negative breast cancer (TNBC): a randomized, double-blind, phase 3 trial
Clinical Cancer Research·2025· 1 cited
Abstract P2-09-17: Precision medicine based on similarity network fusion (SNF) subtypes of multi-omics in CDK4/6 inhibitor failed HR+/ HER2- advanced breast cancer: the Linux trial
Clinical Cancer Research·2025
Camrelizumab vs Placebo in Patients With Triple-Negative Breast Cancer—Reply
JAMA·2025
Using Integrative Therapies to Improve Patient‐Reported Outcomes in Breast Cancer Survivors: A Living Evidence‐Based Clinical Practice Guideline
Journal of Evidence-Based Medicine·2025· 1 citedOpen Access
A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+/HER2‐ breast cancer‐FINEST study
Cancer Communications·2025· 6 citedOpen Access
Photoelectron superlubricity
arXiv (Cornell University)·2024Open Access
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
JAMA·2024· 33 citedOpen Access
Elongin B promotes breast cancer progression by ubiquitinating tumor suppressor p14/ARF
Cell Biology and Toxicology·2024· 4 citedOpen Access
Genetic interactions reveal distinct biological and therapeutic implications in breast cancer
Cancer Cell·2024· 26 citedOpen Access
Omicron breakthrough infections after triple‐dose inactivated <scp>COVID</scp>‐19 vaccination: A comprehensive analysis of antibody and T‐cell responses
Immunology·2024· 2 citedOpen Access
Revealing the pharmacological effects of Remodelin against osteosarcoma based on network pharmacology, acRIP-seq and experimental validation
Scientific Reports·2024· 6 citedOpen Access
Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial
The Lancet Oncology·2024· 55 cited
Immune Checkpoint Inhibitors in Triple-negative Breast Cancer
Nature Cell and Science·2023· 1 citedOpen Access
Comprehensive genomic profiling of breast cancers characterizes germline-somatic mutation interactions mediating therapeutic vulnerabilities
Cell Discovery·2023· 28 citedOpen Access
Prognostic factors and clinical outcomes of breast cancer patients with disease progression during neoadjuvant systemic therapy
The Breast·2023· 5 citedOpen Access
FUTURE-SUPER: A randomized, subtyping-based umbrella phase II trial for first-line treatment of metastatic triple-negative breast cancer.
Journal of Clinical Oncology·2023· 2 cited
ac4C acetylation regulates mRNA stability and translation efficiency in osteosarcoma
Heliyon·2023· 26 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Ke‐Da Yu(19), Zhi‐Ming Shao(11), Zhi‐Ming Shao(8), Gen‐Hong Di(8), Jiong Wu(6), Suhua Chen(6), Chen Yang(6), Canqing Yu(5), Juan Xiao(5), Wei Li(5), Nan Yu(4), Jianli Wu(4), Aji Huang(4), Yi‐Zhou Jiang(4), Ao-Xiang Chen(4), Junjie Li(3), Ding Ma(3), Guang‐Yu Liu(3), Kejin Wu(3), Zhigang Zhuang(3)